Biofrontera Inc.: A Dermatology Company Scaling with Momentum
April 8, 2026
Clinically Proven. Commercially Scaling.
Record revenue. Third profitable quarter. Phase 3 success. In Q4 2025, Biofrontera delivered on all three — signaling a shift from development-stage story to commercial-stage execution, with multiple near-term catalysts ahead.
What Is Photodynamic Therapy?
Photodynamic therapy (PDT) uses a light-activated drug applied directly to the skin to destroy precancerous and cancerous cells with precision — avoiding the scarring and systemic side effects of surgery or oral medications. Biofrontera’s Ameluz® gel, paired with the RhodoLED® lamp, is the only red-light PDT system FDA-approved for actinic keratosis in the U.S. Treatment is performed in-office in under 90 minutes with established insurance reimbursement, making it both clinically effective and commercially practical.
Actinic keratosis (AK) is the most common precancerous skin condition — over 40 million Americans develop AKs each year, with approximately 13 million treatments performed annually. Left untreated, AKs can progress to squamous cell carcinoma. PDT offers field treatment that addresses both visible lesions and the surrounding sun-damaged skin, reducing recurrence rates compared to spot treatments like cryotherapy.
The Investment Case
Financial Momentum
| Metric | Q4 2025 | Q4 2024 |
|---|---|---|
| Revenue | $17.1M (+36%) | $12.6M |
| Gross Margin | 82.4% | 58.0% |
| Net Income / (Loss) | +$5.6M | ($1.4M) |
| Adjusted EBITDA | +$4.9M | ($1.4M) |
| Full Year Revenue | $41.7M (+12%) | $37.3M |
Q4 2025 was Biofrontera’s most profitable quarter — and the improvement is structural, not one-time. Gross margins expanded by ~2,400 basis points year-over-year because the company now owns 100% of its U.S. intellectual property, regulatory approvals, and manufacturing rights following the strategic transaction with Biofrontera AG. The legacy transfer pricing model (25–35% of net sales) has been replaced with a significantly lower 12–15% earnout structure. This cost advantage is permanent and fully annualized in 2026.
Latest News:
- Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
- Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
- Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
About Us
Clinical Validation Across Multiple Indications
Biofrontera is the only company in the U.S. actively advancing FDA-regulated PDT clinical programs in dermatology. Three pipeline programs are progressing simultaneously:
- AK on Extremities, Neck & Trunk (Phase 3 — POSITIVE): Study met its primary endpoint with high statistical significance (p < 0.0003). Complete clearance rates reached 45.6% vs. 16.7% for control. This data supports an sNDA filing in H2 2026 to expand the Ameluz label beyond the face and scalp, opening access to the majority of AK lesions that occur on the body.
- Superficial Basal Cell Carcinoma (sNDA Filed — PDUFA Sep 2026): FDA has accepted the filing and assigned a PDUFA target action date of September 2026. If approved, Ameluz would become the first FDA-approved PDT for skin cancer in the U.S., entering a large and growing market.
- Moderate-to-Severe Acne Vulgaris (Phase 2b — POSITIVE): Positive Phase 2b results support further development in a $5+ billion U.S. acne treatment market. Ameluz PDT offers a non-antibiotic, in-office option for a condition where antibiotic resistance is a growing concern.
Competitive Positioning
Biofrontera holds a differentiated position in the U.S. PDT market. Ameluz is one of only two FDA-approved aminolevulinic acid photosensitizers for AK — and the only one paired with proprietary red-light LED technology (RhodoLED®). Patent protection extends through 2043, providing long-term exclusivity for the platform.
Upcoming Catalysts
- Sep 2026: sBCC PDUFA Date — FDA target action date for supplemental NDA for superficial basal cell carcinoma. Potential first-ever FDA-approved PDT for skin cancer in the U.S.
- H2 2026: sNDA Filing — Supplemental NDA submission for AK on extremities, neck, and trunk based on positive Phase 3 data. Expands addressable treatment areas beyond face/scalp.
- 2026: Full-Year Cost Structure Benefit — First full year reflecting the reduced earnout (12–15% vs. prior 25–35%), supporting sustained margin expansion and path to full-year profitability.
- 2026–2027: Acne Program Advancement — Next steps in clinical development for moderate-to-severe acne vulgaris following positive Phase 2b results.
- Through 2043: Patent Protection — Long-term IP exclusivity on the Ameluz PDT platform across current and pipeline indications.